stockrow
Saturday 7 November 2026
Export ALMS’s income statement to Excel — free account
Alumis Inc.
ALMS Healthcare Biotechnology
Alumis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $24.1 million.
- Revenue
- −37.7%
- EPS
- −242.3%
- Free cash flow
- +23.6%
Quarter to June 2026, against a year earlier
6.02
0.17
+2.91%
Follow ALMS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 24 | 7 | — | 6 | 24 | 156 | +86.6% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | 100.00 | 100.00 | — | ||||||
| EBT | — | — | — | — | — | — | — | (155) | (294) | (252) | (441) | +27.5% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | (1,047.34) | (5,957.20) | (1,047.3) pt | ||||||
| Net income | — | — | — | — | — | — | — | (155) | (294) | (243) | (439) | +25.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.28 | 0.06 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | (72.08) | (10.38) | (2.86) | (3.79) | (80.1%) | ||||||
| Cash flow | — | — | — | — | — | — | — | (60.45) | (9.00) | (4.35) | (2.75) | (73.2%) | ||||||
| Capex | — | — | — | — | — | — | — | (2.09) | (0.06) | (0.01) | 0.00 | (93.9%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (62.54) | (9.06) | (4.35) | (2.76) | (73.6%) | ||||||
| Book value | — | — | — | — | — | — | — | (157.78) | 9.18 | 3.54 | 3.54 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | 2 | 28 | 85 | 110 | +528.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | 34.51 | 103.91 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | 2.75 | 1.70 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 21.68 | 36.01 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (1.41) | (0.76) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (130) | (255) | (370) | (351) | +68.6% | |||||
| Capex | — | — | — | — | — | — | — | (4) | (2) | (1) | 0 | (61.9%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (134) | (257) | (370) | (352) | +65.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 32 | 255 | 245 | 438 | +174.6% | |||||
| Net debt | — | — | — | — | — | — | — | (49) | (288) | (309) | (502) | +150.8% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | (339) | 260 | 301 | 452 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (136.66) | (64.63) | (74.94) | (64.6) pt | |||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | 743.43 | (86.68) | (93.65) | (86.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 109 | 170 | 224 | — | +43.4% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.11 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Alumis Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $843.6M | — (loss-making) | — (loss-making) | +81.59% (above 0%: growing) | n/m | +61.43% (above 0%: growing) | 83.20% | (50.30%) | Compare |
| AKTS Aktis Oncology, Inc. | $826.0M | — (loss-making) | — (loss-making) | — | n/m | −12.77% (below 0%: shrinking) | 100.00% | (853.99%) | Compare |
| CRVS Corvus Pharmaceuticals, Inc. | $818.5M | — (loss-making) | — | — | n/m | −171.31% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MGTX MeiraGTx Holdings PLC | $817.3M | 11.8× | 30.3× | +8,608.59% (above 0%: growing) | n/m | +13.06% (above 0%: growing) | 97.77% | 76.04% | Compare |
| PRME Prime Medicine, Inc. | $807.1M | — (loss-making) | — (loss-making) | +3.50% (above 0%: growing) | n/m | +4.40% (above 0%: growing) | 100.00% | (3,750.87%) | Compare |
| ALMS Alumis Inc. | $780.9M | — (loss-making) | — (loss-making) | −37.66% (below 0%: shrinking) | n/m | +23.59% (above 0%: growing) | 100.00% | (8,956.38%) | |
| ANNX Annexon, Inc. | $759.3M | — (loss-making) | — | — | n/m | −26.41% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARDX Ardelyx, Inc. | $751.6M | — (loss-making) | — (loss-making) | +15.70% (above 0%: growing) | n/m | +938.76% (above 0%: growing) | 96.44% | 3.15% | Compare |
| LXRX Lexicon Pharmaceuticals, Inc. | $716.4M | — (loss-making) | — (loss-making) | −20.67% (below 0%: shrinking) | n/m | +66.10% (above 0%: growing) | 99.30% | (128.84%) | Compare |
| Median of peers | $812.2M | — | — | +15.70% | — | +8.73% | 97.11% | (25.15%) |
Pay and ownership Proxy statement filed 18 May 2026
Ownership
Directors and executive officers, together
33.70% of the votes
Entities affiliated with Foresite Capital Management
12.70% of the votes
James B. Tananbaum, M.D.
12.70% of the votes
AyurMaya Capital Management Fund, LP
12.30% of the votes
Alan Colowick, M.D., M.P.H.
12.30% of the votes
Entities affiliated with Deep Track Capital, LP
6.00% of the votes
Samsara BioCapital, L.P.
5.10% of the votes
Srinivas Akkaraju, M.D., Ph.D.
5.10% of the votes
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement